denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Education Program
Session: How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023?
Hematology Disease Topics & Pathways:
Research, clinical trials, Lymphoid Leukemias, Biological therapies, adult, Clinical Practice (Health Services and Quality), CLL, elderly, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Combination therapy, Diseases, real-world evidence, Therapies, Lymphoid Malignancies, Monoclonal Antibody Therapy, emerging technologies, Technology and Procedures, Study Population, Human, Minimal Residual Disease , molecular testing
Session: How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023?
Hematology Disease Topics & Pathways:
Research, clinical trials, Lymphoid Leukemias, Biological therapies, adult, Clinical Practice (Health Services and Quality), CLL, elderly, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Combination therapy, Diseases, real-world evidence, Therapies, Lymphoid Malignancies, Monoclonal Antibody Therapy, emerging technologies, Technology and Procedures, Study Population, Human, Minimal Residual Disease , molecular testing
Saturday, December 9, 2023, 2:00 PM-3:15 PM
Disclosures: Rhodes: Jannsen: Consultancy; Pharmacyclics: Consultancy, Research Funding; Beigene: Consultancy; AstraZeneca: Consultancy; Morphosys: Consultancy; Velosbio: Research Funding; SeaGen: Honoraria; Oncternal Pharmaceuticals: Research Funding; Acerta: Research Funding; Loxo Oncology: Research Funding; ADC Therapeutics: Consultancy; Epizyme: Consultancy, Research Funding; GenMab: Consultancy; Genetech: Consultancy; Abbvie: Consultancy, Research Funding.
See more of: How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023?
See more of: Education Program
See more of: Education Program